Mmastodon HealthHealth first seen 2 d ago, last 1 d ago, peak #1

Five-year PHERGain results support chemo-sparing approach in HER2-positive breast cancer

Original: Five-year PHERGain results support a PET- and pathology-guided strategy that spared some women with early HER2-positive

Five-year results from the phase 2 PHERGain trial support a PET- and pathology-guided strategy that allowed some women with early HER2-positive breast cancer to avoid chemotherapy. The trial was not designed to prove equivalence with standard treatment, and the chemotherapy-free subgroup was small, so experts urge cautious interpretation while the findings are being discussed.

Why now: New long-term PHERGain trial data were presented, renewing debate over whether some HER2-positive patients can safely skip chemotherapy

PHERGain trialHER2-positive breast cancerPET imaging

Open on mastodon →

Rank over time, top of the chart is #1. 3 snapshots from 2 d ago to 1 d ago.

Evidence

• Five-year PHERGain results support a PET- and pathology-guided strategy that spared some women with early HER2-positive breast cancer from chemotherapy. The phase 2 trial was not designed to prove equivalence with standard treatment, and its chemotherapy-free subgroup was… · news@newtqnia.com · 2

API: https://socialmediatrends-api.osmike.com/v1/trends/4480186